Real-World study reveals how anesthesia reversal drug is actually used
NCT ID NCT05788718
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study observed over 6,400 adults undergoing elective surgery to see how doctors prescribe sugammadex, a drug that reverses muscle paralysis from anesthesia. Researchers collected data from routine care, without extra tests or treatments. The goal was to understand prescription patterns and check the drug's safety and effectiveness in everyday hospital settings.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Sugammadex
- What this could lead to
- If successful, this study could confirm that sugammadex is used safely and effectively in everyday medical practice, helping doctors make better decisions.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by factors like patient differences or doctor choices.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
6,458 people
The number who actually took part.
- Started
-
Apr 2023
- Finished
-
May 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients who are planning to undergo surgery using rocuronium or vecuronium for the neuromuscular blockade and planned to receive sugammadex for the antagonist.
- Ages
-
19 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male or female adults aged 19 or older * Is to undergo elective surgery under general anesthesia * Is planned to use rocuronium or vecuronium as an NMBA * Is planned for extubation before/after being moved to the recovery room * ASA physical status I - III * Patients who have signed the informed consent after receiving information about the purpose and method of this study Exclusion Criteria: * Has myasthenia gravis or Eaton-Lambert myasthenic syndrome * Has hypersensitivity to ingredients of sugammadex, rocuronium, or vecuronium * Has received an investigational product within 12 weeks from the study enrollment or has plans to participate in another clinical trial during the participation of this study. * Other subjects who are considered inappropriate to participate in this study by the judgment of the investigator.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Anesthesia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Korea University Anam Hospital
Seoul, Seongbuk-gu, 02841, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Newer sedative faces off against propofol in heart patients
- Could a whiff of xenon replace the Pre-Surgery chill pill?
- Muscle relaxant dose may hold key to better breathing tube alternative
- A standard IV fluid dose may reveal who is at risk after bowel surgery
- Which nerve monitor tells the truth in toddlers?
- Can a common blood pressure drug make anesthesia safer for the very old?